Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66779-1-Ig - Provider product page

- Provider
- Proteintech Group
- Product name
- CD16 antibody
- Antibody type
- Monoclonal
- Description
- CD16 antibody (Cat. #66779-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human and has been validated for the following applications: IHC,ELISA.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1E12E11
- Vial size
- 20ul, 150ul
Submitted references Molecular mechanism of Flt-1 protein and the regulation of monocytes modulate endothelial cell in wound healing sites via PGF/FLT1 signaling.
Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells.
IL-2 Combined with IL-15 Enhanced the Expression of NKG2D Receptor on Patient Autologous NK Cells to Inhibit Wilms' Tumor via MAPK Signaling Pathway.
Lu L, Wu Y, Lu C, Liang F, Gu S, Sun S, Tang Q, Tang Q
International journal of biological macromolecules 2025 May;307(Pt 3):142192
International journal of biological macromolecules 2025 May;307(Pt 3):142192
Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells.
He Y, Yang D, Lin X, Zhang J, Cheng R, Cao L, Yang L, Zhang M, Shi X, Jin X, Sun H, Sun H, Zang J, Li Y, Ma J, Nie H
Frontiers in immunology 2024;15:1412693
Frontiers in immunology 2024;15:1412693
IL-2 Combined with IL-15 Enhanced the Expression of NKG2D Receptor on Patient Autologous NK Cells to Inhibit Wilms' Tumor via MAPK Signaling Pathway.
Li Y, Li Y, Xiang B, Tian X, Shi Q, Liu F, Lin T, Wei G
Journal of oncology 2022;2022:4544773
Journal of oncology 2022;2022:4544773
No comments: Submit comment
No validations: Submit validation data